“That said, advanced imaging modalities—Axumin PET and PSMA PET—are the hottest topic, if you will,” Dr. Morgan told Urology Times. “I think arguably there is no bigger change coming down the pike in prostate cancer care over the next 5 years than those imaging modalities, especially in the biochemically recurrent setting or the oligometastic disease setting.”
December 11, 2018
Urology Times speaks to U-M Urology regarding the standard of care for imaging in advanced prostate cancer
Dr. Todd Morgan spoke on computed tomography and bone scans, among other options